A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business. iBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence (“AI”) for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space. Our core mission is to harness the potential of AI and machine learning (“ML”) to unveil novel biologics which other scientists have been unable to develop. Through our innovative AI Drug Discovery Platform, we have been able to identify differentiated molecules aimed to address unmet needs by current glucagon-like peptide-1 (“GLP-1”) receptor agonists. We believe the future of obesity care lies not just in weight loss—but in quality weight loss. Current interventional therapies such as GLP-1 receptor agonists have ushered in a breakthrough era, yet challenges remain: muscle loss, fat regain after treatment cessation, and long-term tolerability.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 300K | - | - | 0 | - | - |
| Net Income | -25M | -18M | -25M | - | -50M | -23M |
| EPS | $-1.00 | $-1.75 | $-6.50 | $-2,123.80 | $-2,890.00 | $-1,500.00 |
| Free Cash Flow | -19M | -15M | -19M | -36M | -45M | -35M |
| ROIC | -31.3% | -101.2% | -116.5% | - | -79.2% | -16.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.19 | 0.18 | 0.28 | 0.76 | 0.30 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -25M | -19M | -17M | -29M | -30M | -31M |
| Operating Margin | -8491.0% | - | - | - | - | - |
| ROE | -43.7% | -101.5% | -116.8% | - | -79.2% | -21.6% |
| Shares Outstanding | 35M | 11M | 20M | 0M | 0M | 0M |
iBio, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
iBio, Inc. (IBIO) has a 5-year average return on invested capital (ROIC) of -78.4%. This is below average and may indicate limited pricing power.
iBio, Inc. (IBIO) has a market capitalization of $76M. It is classified as a small-cap stock.
iBio, Inc. (IBIO) does not currently pay a regular dividend.
iBio, Inc. (IBIO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
iBio, Inc. (IBIO) generated $-15 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
iBio, Inc. (IBIO) has a debt-to-equity ratio of 0.19. This indicates a conservatively financed balance sheet.
iBio, Inc. (IBIO) reported earnings per share (EPS) of $-1.75 in its most recent fiscal year.
iBio, Inc. (IBIO) has a return on equity (ROE) of -101.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for iBio, Inc. (IBIO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
iBio, Inc. (IBIO) has a book value per share of $1.42, based on its most recent annual SEC filing.